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ABSTRACT Exogenous, orally-administered enzymes are
currently in clinical use or under development for the treatment of
pathologies, such as celiac disease and phenylketonuria. However,
the administration of therapeutic enzymes via the oral route remains
challenging due to potential inactivation of these fragile
macromolecular entities in the harsh environment of the
gastrointestinal tract. Enzymes are particularly sensitive because both
proteolysis and unfolding can lead to their inactivation. Current efforts
to overcome these shortcomings involve the application of gastro-
resistant delivery systems and the modification of enzyme structures
by polymer conjugation or protein engineering. This perspective
manuscript reviews and critically discusses recent progress in the oral
delivery of therapeutic enzymes, whose substrate is localized in the
gastrointestinal tract.
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INTRODUCTION
Enzymes are widely used as therapeutic agents and research
tools to elucidate molecular pathways (1). As drugs, they are of
particular interest because of their high activity and selectivity,
and because of the possibility of manipulating these properties
through chemical (2) and protein engineering techniques (3).
However, due to their complex structure, enzymes are
potentially subject to inactivation, especially when
administered via the oral route (1). Indeed, it is difficult to
stabilize proteins in the gastrointestinal (GI) tract as its primary
function is protein digestion (Fig. 1). Despite this paramount
challenge, the concept of oral enzyme replacement therapy
has been around for some time with a certain degree of success
(4), and a number of stabilization strategies have been
investigated (functional modifications (2) or formulation
approaches (5)). The goal of oral enzyme therapy is to either
degrade potentially harmful food components in situ (celiac
disease, phenylketonuria) or supplement the organism with
digestive enzymes produced in insufficient amounts (exocrine
pancreatic insufficiency, disaccharidase deficiencies). This
perspective manuscript reviews state-of-the-art oral enzyme
therapies against diseases in which activity of the administered
enzyme is desired in the GI tract, and not after systemic
absorption (e.g., adjuvant therapy in oncology (6)) or when
delivered via probiotics (7). Stabilization strategies are
highlighted and built upon to shape future research directions.
THE GI TRACT—A HARSH AND DYNAMIC
ENVIRONMENT
Modern delivery strategies should aim at stabilizing orally-
administered enzymes at different locations in the GI tract (for
maximal activity) and at a reasonable cost, since doses of
exogenous enzymes are often quite high (e.g ., up to a few g/
day). Stabilization and selective re-activation in different
segments of the GI tract can be achieved with various
approaches that exploit the intrinsic chemical environments
encountered at these locations.
Themammalian digestive system is divided into the stomach,
small intestine (duodenum, jejunum, and ileum) and large
intestine (cecum, colon, rectum, and anal canal) (Fig. 1). Protein
digestion begins in the low pH environment of the stomach and
involves peptidases (7). In particular, pepsin has a propensity to
hydrolyze peptide bonds at hydrophobic residues such as
phenylalanine and leucine, while residues such as histidine,
lysine, arginine, and proline are left untouched (8). This process
is facilitated by protein unfolding at acidic pH (1–2.5) (1). As
both mechanisms act synergistically and are very efficient,
digestion in the stomach is the main obstacle encountered by
oral enzyme formulations. Upon leaving the stomach and
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entering the small intestine, pH increases to neutral values (7).
Although most exogenous enzymes are stable a priori in these
environments, they can be degraded by pancreatic peptidases
(mainly trypsin and chymotrypsin) (1). Trypsin and chymotrypsin
are endopeptidases that preferentially cleave peptide bonds
involving arginine, lysine and aromatic amino acids, respectively.
In addition, therapeutic enzymes are potentially subject to
denaturation by intestinal bile salts (7) (Fig. 1).
One approach to overcome digestion in the GI environment
is to manipulate the primary sequence of proteins by
recombinant technologies to reduce their propensity to unfold
in acidic media, and to lower their susceptibility to pepsin-
mediated digestion. For instance, replacement of phenylalanine
and leucine residues by analogues which are less recognized by
pepsin has been explored (9). In addition, to completely avoid
digestion in the stomach, gastro-resistant, polymer-coated tablets
or microparticles (prepared e.g. with cellulose acetate phthalate
or methacrylate copolymers) can be used (10,11). These coatings
dissolve in the higher pH environment of the small intestine (see
below), thereby releasing therapeutic enzymes. Another way to
improve enzymeGI stability is covalent conjugation to polymers
(5). This method provides protein protection mainly through
steric shielding from endogenous proteins and has been mostly
exploited to stabilize enzymes administered by intravenous
injection (e.g ., poly(ethylene glycol) (PEG)-L-asparaginase (12)
or PEG-recombinant uricase (13)).
Key points associated with the oral delivery of therapeutic
enzymes are summarized in Table I. Advantages and
drawbacks of current strategies against different GI disorders
are discussed in the following sections.
Fig. 1 Current concepts of enzyme stabilization in the GI tract. Upon oral administration, exogenous enzymes encounter different environments in the GI tract
(7) (stomach, small, and large intestine). (i) Digestion by stomach peptidases (e.g., pepsin) and/or (ii) pH-induced protein unfolding result in enzyme inactivation.
(iii) Inactivated enzymes cannot digest their substrate. (iv) Enzyme inactivation can be overcome by enteric coating, polymer conjugation and protein engineering.
(v) Enzyme-polymer conjugates and bioengineered enzymes but not enteric-coated formulations could, in principle, cleave their substrates in the stomach. After
transit to the small intestine, (vi) enteric coatings dissolve, releasing enzymes, (vii) which are potentially subject to inactivation by pancreatic peptidases and bile salts.
(viii) Such inactivation of enzyme-polymer conjugates and bioengineered enzymes may also be avoided or slowed down. (ix) Enzymes cleave their substrate in the
intestine which (x) allows normal absorption of nutrients.
Table 1 Oral Enzyme Therapy: Applications and Challenges
Key points
• Orally-administered exogenous enzymes can serve to treat several GI and
non-GI diseases
• Enzymes are potentially subject to inactivation in the harsh GI environment
• Stability can be enhanced via enteric coating, polymer modification, and
protein engineering
1100 Fuhrmann and Leroux
SUCROSE INTOLERANCE: AN EXCEPTION?
Not all oral therapeutic enzymes require specific delivery
systems because they show significant intrinsic stability under
GI conditions. One example is sacrosidase which is used for
the treatment of congenital sucrose-isomaltase intolerance (~1
in 500 white ethnics (14)). Affected patients cannot digest the
disaccharide sucrose, leading to its malabsorption. This
culminates in considerable abdominal distension, bloating,
diarrhea, and failure to thrive (14). Although strict exclusion
of sucrose-containing food overcomes these issues, such a diet
is difficult to follow, especially in children. Clinical
improvement of symptoms is seen after oral administration
of yeast extract (14) (preferably on a filled stomach) and
treatment with oral sacrosidase solution (15). The sacrosidase
solution was found to be exceptionally resistant to acidic
environments due to enzyme glycosylation and its use at high
concentrations. Moreover, it could escape pepsin digestion
in vitro in the presence of “sacrificial” protein substrates (16)
that competed for degradation (Table II). It would therefore
be advisable to administer sacrosidase with a protein-
containing meal, although concomitantly-ingested food may
also promote degradation by increasing both residence time in
the stomach and the secretion of pancreatic enzymes.
LACTOSE INTOLERANCE
Lactose intolerance (i.e. , adult-type hypolactasia) is a common
autosomal recessive disease characterized by a deficit in
lactase-phlorizin hydrolase, an enzyme hydrolyzing lactose
into glucose and galactose (17). The prevalence of this
predisposition varies greatly, between 5% in Europe and up
to 90% in certain populations from Asia and Africa (18). Its
onset often occurs 1–2 years after weaning, and is associated
with abdominal bloating and diarrhea but also alterations of
bone mineral density due to calcium deficiency (19). Although
most people with hypolactasia tolerate moderate amounts of
lactose (approximately 12 g/day (20)), the disease can be
treated by excluding lactose-containing products from the
diet. Such diet is also difficult to maintain due to undersupply
with calcium, phosphate and vitamins, but alternatives are
available. For example, β-galactosidase can be added to milk
prior to consumption, administered directly with a lactose-
containing meal (21), or can be consumed as yoghurt (22).
Although the concept of enzyme replacement works, oral β-
galactosidase application often leads to reduced therapeutic
efficiency compared to pre-hydrolyzed milk (23). This effect is
presumably attributed to GI inactivation of the enzyme.
Comparative studies of different lactase digestive supplements
have shown low to moderate in vitro enzyme stability under
simulated GI conditions (24) (especially in simulated gastric
environments) (Table II). To overcome these limitations, β-
galactosidase was recently modified chemically with branched
40-kDa PEG, a hydrophilic polymer which creates a zone of
steric hindrance around the enzyme. Steric hindrance should
be controlled to prevent the action of endogenous digestive
enzymes while allowing the substrate to reach catalytic sites
(25). The conjugate displayed enhanced stability at acidic
pH and in simulated gastric fluids containing pepsin (26)
(Table II). Alternatively, a bioengineered β-galactosidase
mutant (27) and hydrolase isolated from meso-acidophilic
fungus (28) have both demonstrated improved stability at
low pH (Table II). However, it is still not known if these
enzymes would better survive hydrolysis by gastric and
pancreatic enzymes.
EXOCRINE PANCREATIC INSUFFICIENCY
Exocrine pancreatic insufficiency, resulting from pancreatic
problems, is characterized by a deficiency or absence of
certain digestive enzymes (i.e. , amylase, proteases, and lipases)
(29). The main causes of insufficient pancreatic secretion
include cystic fibrosis (30), pancreatic cancer (10), and chronic
pancreatitis (reported to be the main cause of pancreatic
insufficiency affecting 0.5–4% worldwide (31)). In
addition, pancreatic insufficiency is frequent in type 1
(51% prevalence) and type 2 (32% prevalence) diabetes
(32). Impairment of pancreatic enzyme secretion is
associated with insufficient digestion and, consequently,
malabsorption/malnutrition, steatorrhea, and body
weight loss. Exocrine pancreatic insufficiency may
conceal other GI diseases, making their diagnoses challenging
(33). Some studies have also analyzed the potential connection
between exocrine pancreatic insufficiency and persistent
symptoms in adult celiac (34) and inflammatory bowel disease
patients (33). In both cases, supplementation with pancreatic
enzymes should be considered as it might improve GI
symptoms (35).
The therapy of choice in pancreatic insufficiency is
supplementation with bovine and porcine pancreatic enzymes
preferably in gastro-resistant (enteric-coated) microspheres
(10,11,31). Enteric coating protects enzymes in the stomach
and releases them during transit to the duodenum alongside
food (11) (Table II). Although oral administration of
pancreatic enzymes in enteric formulations has been
demonstrated to improve symptoms of malabsorption in
patients with pancreatic insufficiency due to human
immunodeficiency virus (36), the general therapeutic benefit
of these systems remains debatable (4). Comparison between
different coated and uncoated microsphere formulations has
revealed that bioavailability can fluctuate substantially
between products, leading to possible discrepancies in oral
activity of the enzymes (37). In addition, malnutrition often
persists in patients with pancreatic insufficiency, despite
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enzyme supplementation, calling for the development of new
methods of clinical evaluation of oral enzyme substitution
efficiency (38). In general, depending on the primary cause
of pancreatic insufficiency (e.g. , cystic fibrosis), acidic
conditions in the intestine can delay enzyme release and thus
affect the clinical outcome of the therapy (37). Recently, a
mutant of Thermomyces lanuginosus lipase has been suggested as
potential enzyme replacement candidate. Although both
native enzyme and variant showed comparable resistance
towards trypsin (with and without bile salts), the mutant
was reported to be more stable at acidic pH and
showed increased refolding capacity compared to the
native lipase (39) (Table II). The conjugation of
synthetic polymers to enzymes could also overcome
drawbacks related to substitution therapy by delivering
functionally-modified enzymes in the duodenum without
relying on prior dissolution of enteric coating. Although
pancreatic enzymes (trypsin or chymotrypsin) frequently
serve as model enzymes to explore the impact of
polymer-protein modifications (40), their systematic
analysis after oral administration is still lacking.
However, in this specif ic application, polymer
conjugation might be viewed as being expensive for
the formulation of porcine pancreatic enzymes, and
should perhaps be restricted to more specialized
enzymes (see below).
CELIAC DISEASE
Celiac disease (1 in 100 white ethnics (41)) is a life-long,
genetically-inherited disease triggered by the ingestion of
cereal proteins (i.e. , gluten) from wheat, barley, and rye (42).
Insufficient digestion of these proteins induces a T cell-
controlled autoimmune reaction precipitated in the small
intestine of genetically-predisposed patients. This
inflammation is associated with GI-related (e.g. , diarrhea,
malabsorption, abdominal pain) and non-GI-related (e.g. ,
osteoporosis, anemia, migraine) symptoms (43). Moreover,
overall mortality is higher among celiac patients than the
general population (44). To date, strict exclusion of gluten
from daily nutrition is the only available treatment (45). Such
a diet is challenging for affected people and is difficult to follow
(43). Different treatment options are currently being explored,
among which the oral administration of gluten-degrading
enzymes appears to be promising (41,46). The latter approach
consists of digesting immunogenic andGI-resistant glutamine-
and proline-rich peptides of gluten with proline-specific
endopeptidases (PEPs) (47) and barley endoprotease (EP-
B2). PEPs, derived from different bacterial and fungal sources,
have reached clinical testing (48,49). In clinical phase I trials,
PEPs were well tolerated (49,50), and PEP and EP-B2
combination significantly reduced gluten in vivo under fed
stomach conditions (50). However, the sensitivity of some
PEPs to acidic gastric conditions and their potential
degradation by intestinal fluids and bile salts remain
problematic (1,51). To address the first issue, PEPs have been
incorporated in enteric-coated capsules (52). In vitro, this
formulation was efficient in protecting PEPs from inactivation
under simulated gastric conditions, but was not tested later in
humans. It could be questioned whether enteric formulation
of PEPs could be the best option here, since gluten should be
preferentially degraded in the upper GI tract before
immunogenic peptide sequences reach the jejunum
(Table II). Moreover, enteric PEP formulations would not
protect them from digestion in intestinal fluids. Protein
engineering of PEPs appears to be more promising because
it does not impair enzymatic activity in a specific section of the
GI tract. A series of PEP mutants with increased gastric
enzyme stability in vitro (9) have been obtained with this
Table II Strategies to Enhance the GI Stability of Exogenous Enzymes
Disease Oral enzyme Delivery approach Effect References
Sucrose intolerance Sacrosidase None Prolonged activity in the presence
of alimentary proteins
Treem et al. (1993) (16)
Lactose intolerance Lactase Enteric-coated formulations Improved in vitro stability in
gastric fluids
O’Connell & Walsh (2006) (24)
β-galactosidase Polymer conjugation Turner et al. (2011) (26)
β-galactosidase Recombinant expression of
mutants
O’Connell & Walsh (2010) (27)
Pancreatic insufficiency Pancreatic enzymes Enteric-coated microspheres Improved in vitro stability in
gastric fluids
Domínguez–Muñoz (2011) (11)
Lipase Enzyme variant Wang et al. (2013) (39)
Celiac disease Proline-specific
endopeptidases
Enteric-coated capsules Improved in vitro stability in gastric fluids Gass et al. (2005) (52)
Protein engineering Enhanced in vitro stability and activity Gordon et al. (2012) (53)
Polymer conjugation Enhanced in vivo activity Fuhrmann et al. (2013) (55)
Phenylketonuria Phenylalanine hydroxylase Fusion protein Reduction of plasma phenylalanine
levels in mice
Eavri & Lorberboum-Galski
(2007) (64)
Phenylalanine ammonia lyase Polymer conjugation Sarkissian et al. (2008) (61)
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approach. Interestingly, improvement of stability towards
pepsin at low pH was not only attributed to changes in the
canonical pepsin specificity pattern (i.e. , replacement of the
pepsin substrates phenylalanine and leucine by disfavored
substrates histidine, lysine, arginine, or proline (8)) but also
mostly to favorable hydrophobic packing that protected the
enzyme from attack of pepsin. In a recent computational-
based study, an acid resistant but gliadin-unspecific enzyme
was mutated to a gliadinase with increased in vitro stability
towards GI enzymes. This engineered enzyme was able to
degrade 95% of a celiac-toxic peptide at simulated stomach
pH (53) (Table II). Additional characterization will clarify
whether this new gliadinase also proves useful in vivo . Another
approach to stabilize PEPs is to conjugate PEG to the enzyme.
PEGylated enzymes show enhanced activity towards gluten
peptides in vitro and improved stability under simulated
intestinal conditions (54). A recent animal study that examined
the activity of PEP-mPEG conjugates by non-invasive real-
time fluorescence assay (1) indicated that the modified
enzyme displayed enhanced activity compared to native
PEPs in the small intestine (55). Very efficient
improvement of PEP performance was obtained by
conjugating them to a dendronized cationic polymer.
PEP-polymer conjugates exhibited prolonged retention
and activity (up to 6 and 3 h, respectively) in the stomach
(55) (Table II). Conjugation of PEPs to specific polymers
in combination with protein engineering methods, to
optimize stability but also to control polymer grafting sites,
could turn out to be a powerful strategy in the future to
produce highly resistant PEPs.
PHENYLKETONURIA
Phenylketonuria (1 in 10,000 white ethnics (56)) is a metabolic
disorder caused by a defect in the gene encoding for the enzyme
phenylalanine hydroxylase (PAH), which catalyzes the
metabolism of phenylalanine to tyrosine. The defect renders
PAH non-functional, leading to phenylalanine accumulation
and, consequently, to impaired neurophysiological function
and reduced cognitive development (57). Current treatment
consists of omitting phenylalanine from the diet, which is
difficult and does not completely reverse neurological damage
(57). Investigated alternatives to this stringent diet include the
administration of tetrahydrobiopterin (a natural cofactor of
PAH), gene therapy to restore PAH levels, and enzyme
replacement with phenylalanine ammonia lyase (PAL) or
recombinant PAH (58). PAL, a comparatively robust enzyme
requiring no cofactors, converts phenylalanine into the
harmless metabolite trans -cinnamate (58). In a proof-of-
principle study, PAL was produced recombinantly in yeast
and successfully tested after oral administration in a mouse
model of human phenylketonuria (59). The concept of
deploying PAL as enzyme replacement therapy was further
examined after PEGylation (60) and pre-clinical screening of
PEGylated PAL from different species (61) (Table II). After
subcutaneous injection, PAL from a cyanobacterium
(Anabaena variabilis ) was found to be the most therapeutically
active enzyme. PAL-mPEG conjugate is currently being
evaluated for safety and tolerability in a phase II clinical
trial. Recently, the short-term pharmacodynamic profile of
PAL-PEG was also assessed after oral administration. PAL
conjugation to 5-kDa PEG produced therapeutically-
relevant reduction of plasma phenylalanine levels in mice
(62) (Table II). Besides PAL, recombinant PAH is being
investigated as potential adjuvant therapy. The stability of
this enzyme was improved by PEGylation (63) and fusion
proteins (64) (Table II). These findings are promising and
need to be validated after oral dosing in preclinical and
clinical trials.
PERSPECTIVES
Oral administration of enzymes is currently indicated for
lactose and sucrose intolerance as well as exocrine pancreatic
insufficiency. There are other conditions (e.g., celiac disease
(41), phenylketonuria (61)) and medical applications (e.g.,
treatment of intoxications (65)) where they could be beneficial.
One such application could be oral administration of phytase,
an enzyme capable of cleaving inositol hexakisphosphate
(IP6), an “anti-nutrient” forming insoluble complexes with
many mineral ions (e.g., Ca2+, Zn2+ and Fe2+) and inducing
mineral deficiencies under cereal- and legume-rich nutrition.
Degradation of IP6 in the intestine by phytase, which appears
to be stable even under gastric conditions, would reduce IP6
concentration and potentially alleviate these deficiencies (66).
Functional GI disorders are other states in which oral
administration of enzymes could be advantageous. α-
Galactosidase can significantly decrease symptoms such as
flatulence in affected patients (67). As with other therapeutic
proteins, however, enzymes are eventually inactivated in the
GI tract, their half-life being determined by their intrinsic
molecular structure and surrounding environment (pH, fed
vs. fasted state, etc.). Current methods to stabilize proteins
mostly rely on enteric coating with debatable clinical
outcome. Thus, there is a need for new non-invasive
techniques to better evaluate enzyme activity in situ and devise
strategies to augment therapeutic efficacy after oral
application. Recent developments in protein engineering
(68) should foster the design of more potent enzyme
formulations (e.g., encapsulation in colloidal carriers to create
“nanoreactors” (65)) with improved stability in the GI tract.
Preliminary data generated recently with polymer
conjugation (55) are encouraging and may stimulate research
in this field.
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